2012 division of medicinal chemistry award address. Trekking the cannabinoid road: A personal perspective

Journal of Medicinal Chemistry

Volumn 57, Issue 10, 2014, Pages 3891-3911

  Makriyannis, Alexandros ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL LIPASE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; LIGAND;

BILAYER MEMBRANE; BINDING SITE; BIOSYNTHESIS; BIOTRANSFORMATION; CELL MEMBRANE; DRUG CONTROL; DRUG INDUSTRY; ENZYME ACTIVE SITE; FLUORINE NUCLEAR MAGNETIC RESONANCE; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; HYDROGEN BOND; LIQUID CHROMATOGRAPHY; MEDICINAL CHEMISTRY; NONHUMAN; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; SOLID STATE; TANDEM MASS SPECTROMETRY;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; AWARDS AND PRIZES; CANNABINOIDS; CHEMISTRY, PHARMACEUTICAL; ENDOCANNABINOIDS; HUMANS; MONOACYLGLYCEROL LIPASES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84901279661     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500220s     Document Type: Review

References (158)

1. Charalambous, A.; Yan, G.; Houston, D. B.; Howlett, A. C.; Compton, D. R.; Martin, B. R.; Makriyannis, A. 5′-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor J. Med. Chem. 1992, 35, 3076-3079
2. Burstein, S. H.; Audette, C. A.; Charalambous, A.; Doyle, S. A.; Guo, Y.; Hunter, S. A.; Makriyannis, A. Detection of cannabinoid receptors by photoaffinity labelling Biochem. Biophys. Res. Commun. 1991, 176, 492-497
3. Pertwee, R.; Griffin, G.; Fernando, S.; Li, X.; Hill, A.; Makriyannis, A. AM630, a competitive cannabinoid receptor antagonist Life Sci. 1995, 56, 1949-1955
4. Guo, J.; Williams, M. K.; Makriyannis, A. Therapeutic opportunities through the modulation of endocannabinoid transport. Pharm. Regul. Aff. 2013, 3, DOI: 10.4172/2167-7689.1000e4123.
5. Picone, R. P.; Khanolkar, A. D.; Xu, W.; Ayotte, L. A.; Thakur, G. A.; Hurst, D. P.; Abood, M. E.; Reggio, P. H.; Fournier, D. J.; Makriyannis, A. ( - )-7′-Isothiocyanato-11-hydroxy-1′,1′- dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor Mol. Pharmacol. 2005, 68, 1623-1635
6. Li, C.; Xu, W.; Vadivel, S. K.; Fan, P.; Makriyannis, A. High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor J. Med. Chem. 2005, 48, 6423-6429
7. Papahatjis, D. P.; Nahmias, V. R.; Nikas, S. P.; Andreou, T.; Alapafuja, S. O.; Tsotinis, A.; Guo, J.; Fan, P.; Makriyannis, A. C1′-cycloalkyl side chain pharmacophore in tetrahydrocannabinols J. Med. Chem. 2007, 50, 4048-4060
8. Lu, D.; Meng, Z.; Thakur, G. A.; Fan, P.; Steed, J.; Tartal, C. L.; Hurst, D. P.; Reggio, P. H.; Deschamps, J. R.; Parrish, D. A.; George, C.; Jarbe, T. U.; Lamb, R. J.; Makriyannis, A. Adamantyl cannabinoids: a novel class of cannabinergic ligands J. Med. Chem. 2005, 48, 4576-4585
9. Xie, X. Q.; Melvin, L. S.; Makriyannis, A. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940 J. Biol. Chem. 1996, 271, 10640-10647
10. Beltramo, M.; Stella, N.; Calignano, A.; Lin, S. Y.; Makriyannis, A.; Piomelli, D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition Science 1997, 277, 1094-1097
11. Thakur, G. A.; Bajaj, S.; Paronis, C.; Peng, Y.; Bowman, A. L.; Barak, L. S.; Caron, M. G.; Parrish, D.; Deschamps, J. R.; Makriyannis, A. Novel adamantyl cannabinoids as CB1 receptor probes J. Med. Chem. 2013, 56, 3904-3921
12. Alapafuja, S. O.; Nikas, S. P.; Bharathan, I. T.; Shukla, V. G.; Nasr, M. L.; Bowman, A. L.; Zvonok, N.; Li, J.; Shi, X.; Engen, J. R.; Makriyannis, A. Sulfonyl fluoride inhibitors of fatty acid amide hydrolase J. Med. Chem. 2012, 55, 10074-10089
13. Nikas, S. P.; Alapafuja, S. O.; Papanastasiou, I.; Paronis, C. A.; Shukla, V. G.; Papahatjis, D. P.; Bowman, A. L.; Halikhedkar, A.; Han, X.; Makriyannis, A. Novel 1′,1′-chain substituted hexahydrocannabinols: 9beta-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist J. Med. Chem. 2010, 53, 6996-7010
14. Karageorgos, I.; Tyukhtenko, S.; Zvonok, N.; Janero, D. R.; Sallum, C.; Makriyannis, A. Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism Mol. BioSyst. 2010, 6, 1381-1388
15. Naidoo, V.; Karanian, D. A.; Vadivel, S. K.; Locklear, J. R.; Wood, J. T.; Nasr, M.; Quizon, P. M.; Graves, E. E.; Shukla, V.; Makriyannis, A.; Bahr, B. A. Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology Neurotherapeutics 2012, 9, 801-813
16. Szymanski, D. W.; Papanastasiou, M.; Melchior, K.; Zvonok, N.; Mercier, R. W.; Janero, D. R.; Thakur, G. A.; Cha, S.; Wu, B.; Karger, B.; Makriyannis, A. Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation J. Proteome Res. 2011, 10, 4789-4798
17. Rapaka, R. S.; Makriyannis, A. Structure-Activity Relationship of the Cannabinoids; DHHS Publication: Rockville, MD, 1987.
18. Naidoo, V.; Nikas, S. P.; Karanian, D. A.; Hwang, J.; Zhao, J.; Wood, J. T.; Alapafuja, S. O.; Vadivel, S. K.; Butler, D.; Makriyannis, A.; Bahr, B. A. A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity J. Mol. Neurosci. 2011, 43, 493-502
19. Fegley, D.; Kathuria, S.; Mercier, R.; Li, C.; Goutopoulos, A.; Makriyannis, A.; Piomelli, D. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172 Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 8756-8761
20. Pei, Y.; Mercier, R. W.; Anday, J. K.; Thakur, G. A.; Zvonok, A. M.; Hurst, D.; Reggio, P. H.; Janero, D. R.; Makriyannis, A. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation Chem. Biol. 2008, 15, 1207-1219
21. Tyukhtenko, S.; Karageorgos, I.; Zvonok, N.; Makriyannis, A. Direct Observation of the pH-Dependent Equilibrium between Open and Closed Conformations of hMGL by NMR Spectroscopy. Presented at the 53rd Experimental NMR Conference, Miami, FL, 2012.
22. Makriyannis, A.; Deng, H. Cannabimimetic Indole Derivatives. Patent WO 01/28557 A1, 2001.
23. Tian, X. Solid State NMR Studies of Interactions of Cannabinergic Ligands with Lipid Membrane Systems. Ph.D. Thesis, University of Connecticut, Storrs, CT, 2009.
24. Tyukhtenko, S.; Jiang, R.; Makriyannis, A.; Guo, J. NMR Characterization of Fatty Acid Binding Proteins (FABPs) Interactions with Anandamide and Novel Selective Inhibitors. Presented at the 54th Experimental NMR Conference, Asilomar, CA, 2013.
25. Karageorgas, I. Towards the Mechanism of Human Monoacylglycerol Lipase (hMGL) Inactivation: A Combination of Mutational Analysis, MS and NMR Approaches. Ph.D. Thesis, Northeastern University, Boston, MA, 2012.
26. Nasr, M. L.; Shi, X.; Bowman, A. L.; Johnson, M.; Zvonok, N.; Janero, D. R.; Vemuri, V. K.; Wales, T. E.; Engen, J. R.; Makriyannis, A. Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire Protein Sci. 2013, 22, 774-787
27. Makriyannis, A.; Guo, J.; Tian, X. Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer Life Sci. 2005, 77, 1605-1611
28. Herkenham, M.; Lynn, A. B.; Little, M. D.; Johnson, M. R.; Melvin, L. S.; de Costa, B. R.; Rice, K. C. Cannabinoid receptor localization in brain Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 1932-1936
29. Yang, D. P.; Banijamali, A.; Charalambous, A.; Marciniak, G.; Makriyannis, A. Solid state 2H-NMR as a method for determining the orientation of cannabinoid analogs in membranes Pharmacol., Biochem. Behav. 1991, 40, 553-557
30. West, J. M.; Zvonok, N.; Whitten, K. M.; Vadivel, S. K.; Bowman, A. L.; Makriyannis, A. Biochemical and mass spectrometric characterization of human N -acylethanolamine-hydrolyzing acid amidase inhibition PLoS One 2012, 7, e43877
31. Mavromoustakos, T.; Yang, D. P.; Charalambous, A.; Herbette, L. G.; Makriyannis, A. Study of the topography of cannabinoids in model membranes using X-ray diffraction Biochim. Biophys. Acta 1990, 1024, 336-344
32. Dixon, D. D.; Tius, M. A.; Thakur, G. A.; Zhou, H.; Bowman, A. L.; Shukla, V. G.; Peng, Y.; Makriyannis, A. C3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor Bioorg. Med. Chem. Lett. 2012, 22, 5322-5325
33. Tian, X.; Guo, J.; Yao, F.; Yang, D. P.; Makriyannis, A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer J. Biol. Chem. 2005, 280, 29788-29795
34. Guo, Y.; Abadji, V.; Morse, K. L.; Fournier, D. J.; Li, X.; Makriyannis, A. ( - )-11-Hydroxy-7′-isothiocyanato-1′,1′-dimethylheptyl- delta 8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain J. Med. Chem. 1994, 37, 3867-3870
35. Ghosh, R.; Todd, A. R.; Wilkinson, S. Cannabis indica. IV. The synthesis of some tetrahydrodibenzopyran derivatives J. Chem. Soc. 1940, 1121-1125
36. Mercier, R. W.; Pei, Y.; Pandarinathan, L.; Janero, D. R.; Zhang, J.; Makriyannis, A. hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation Chem. Biol. 2010, 17, 1132-1142
37. Adams, R.; MacKenzie, S.; Loewe, S. Tetrahydrocannabinol homologs. XVIII. Tetrahydrocannabinol homologs with doubly branched alkyl groups in the 3-position J. Am. Chem. Soc. 1948, 70, 664-668
38. Gaoni, Y.; Hashish, M. R., III. Isolation, structure, and partial synthesis of an active constituent of hashish J. Am. Chem. Soc. 1964, 86, 1646-1647
39. Mechoulam, R.; Braun, P.; Gaoni, Y. Syntheses of.DELTA.1- tetrahydrocannabinol and related cannabinoids J. Am. Chem. Soc. 1972, 94, 6159-6165
40. Razdan, R. K. Structure-activity relationships in cannabinoids Pharmacol. Rev. 1986, 38, 75-149
41. Archer, R. A.; Blanchard, W. B.; Day, W. A.; Johnson, D. W.; Lavagnino, E. R.; Ryan, C. W.; Baldwin, J. E. Cannabinoids. 3. Synthetic approaches to 9-ketocannabinoids. Total synthesis of nabilone J. Org. Chem. 1977, 42, 2277-2284
42. Milne, G. M.; Johnson, M. R. Levonantradol - a role for central prostanoid mechanisms J. Clin. Pharmacol. 1981, 21, S367-S374
43. Devane, W. A.; Dysarz, F. A., 3rd; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 1988, 34, 605-613
44. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
45. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65
46. Van Sickle, M. D.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; Marnett, L. J.; Di Marzo, V.; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A. Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 2005, 310, 329-332
47. Gong, J. P.; Onaivi, E. S.; Ishiguro, H.; Liu, Q. R.; Tagliaferro, P. A.; Brusco, A.; Uhl, G. R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain Brain Res. 2006, 1071, 10-23
48. Devane, W. A.; Hanuš, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992, 258, 1946-1949
49. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 1995, 215, 89-97
50. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 1995, 50, 83-90
51. Williams, J.; Pandarinathan, L.; Wood, J.; Vouros, P.; Makriyannis, A. Endocannabinoid metabolomics: a novel liquid chromatography-mass spectrometry reagent for fatty acid analysis AAPS J. 2006, 8, E655-660
52. Williams, J.; Wood, J.; Pandarinathan, L.; Karanian, D. A.; Bahr, B. A.; Vouros, P.; Makriyannis, A. Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS Anal. Chem. 2007, 79, 5582-5593
53. Wood, J. T.; Williams, J. S.; Pandarinathan, L.; Courville, A.; Keplinger, M. R.; Janero, D. R.; Vouros, P.; Makriyannis, A.; Lammi-Keefe, C. J. Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters Clin. Chem. Lab. Med. 2008, 46, 1289-1295
54. Wood, J. T.; Williams, J. S.; Pandarinathan, L.; Janero, D. R.; Lammi-Keefe, C. J.; Makriyannis, A. Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma J. Lipid Res. 2010, 51, 1416-1423
55. Abadji, V.; Lin, S.; Taha, G.; Griffin, G.; Stevenson, L. A.; Pertwee, R. G.; Makriyannis, A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability J. Med. Chem. 1994, 37, 1889-1893
56. Khanolkar, A. D.; Abadji, V.; Lin, S.; Hill, W. A.; Taha, G.; Abouzid, K.; Meng, Z.; Fan, P.; Makriyannis, A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand J. Med. Chem. 1996, 39, 4515-4519
57. Lin, S.; Khanolkar, A. D.; Fan, P.; Goutopoulos, A.; Qin, C.; Papahadjis, D.; Makriyannis, A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability J. Med. Chem. 1998, 41, 5353-5361
58. Jarbe, T. U.; DiPatrizio, N. V.; Li, C.; Makriyannis, A. Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats Behav. Pharmacol. 2007, 18, 673-680
59. Jarbe, T. U.; Li, C.; Liu, Q.; Makriyannis, A. Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog Psychopharmacology (Berlin, Ger.) 2009, 203, 229-239
60. Xie, X. Q.; Yang, D. P.; Melvin, L. S.; Makriyannis, A. Conformational analysis of the prototype nonclassical cannabinoid CP-47,497, using 2D NMR and computer molecular modeling J. Med. Chem. 1994, 37, 1418-1426
61. Xie, X. Q.; Pavlopoulos, S.; DiMeglio, C. M.; Makriyannis, A. Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling J. Med. Chem. 1998, 41, 167-174
62. Yang, D. P.; Mavromoustakos, T.; Beshah, K.; Makriyannis, A. Amphipathic interactions of cannabinoids with membranes. A comparison between delta 8-THC and its O -methyl analog using differential scanning calorimetry, X-ray diffraction and solid state 2H-NMR Biochim. Biophys. Acta 1992, 1103, 25-36
63. Mavromoustakos, T.; Yang, D. P.; Makriyannis, A. Effects of the anesthetic steroid alphaxalone and its inactive delta 16-analog on the thermotropic properties of membrane bilayers. A model for membrane perturbation Biochim. Biophys. Acta 1995, 1239, 257-264
64. Makriyannis, A. The Role of Cell Membranes in Cannabinoid Activity. In Cannabinoid Receptors; Pertwee, R. G., Ed.; Academic Press: New York, 1995; pp 87-116.
65. Martel, P.; Makriyannis, A.; Mavromoustakos, T.; Kelly, K.; Jeffrey, K. R. Topography of tetrahydrocannabinol in model membranes using neutron diffraction Biochim. Biophys. Acta 1993, 1151, 51-58
66. Guo, J.; Pavlopoulos, S.; Tian, X.; Lu, D.; Nikas, S. P.; Yang, D. P.; Makriyannis, A. Conformational study of lipophilic ligands in phospholipid model membrane systems by solution NMR J. Med. Chem. 2003, 46, 4838-4846
67. Makriyannis, A.; Tian, X.; Guo, J. How lipophilic cannabinergic ligands reach their receptor sites Prostaglandins Other Lipid Mediators 2005, 77, 210-218
68. Xie, X. Q.; Han, X. W.; Chen, J. Z.; Eissenstat, M.; Makriyannis, A. High-resolution NMR and computer modeling studies of the cannabimimetic aminoalkylindole prototype WIN-55212-2 J. Med. Chem. 1999, 42, 4021-4027
69. Makriyannis, A.; Yang, D.P. Solid-State NMR Spectroscopy in the Study of Drug Membrane Interactions; Potential Applications with Antiarrhythmic Agents. In Molecular and Cellular Mechanisms of Antiarrhythmic Agents; Hondeghem, L., Ed.; Futura Publishing Co.: Mount Kisco, NY, 1989; pp 293-305.
70. Makriyannis, A.; Banijamali, A.; Jarrell, H. C.; Yang, D. P. The orientation of ( - )-delta 9-tetrahydrocannabinol in DPPC bilayers as determined from solid-state 2H-NMR Biochim. Biophys. Acta 1989, 986, 141-145
71. Mavromoustakos, T.; Yang, D. P.; Makriyannis, A. Small angle X-ray diffraction and differential scanning calorimetric studies on O -methyl-( - )-delta 8-tetrahydrocannabinol and its 5′ iodinated derivative in membrane bilayers Biochim. Biophys. Acta 1995, 1237, 183-188
72. Mavromoustakos, T.; Yang, D. P.; Broderick, W.; Fournier, D.; Makriyannis, A. Small angle X-ray diffraction studies on the topography of cannabinoids in synaptic plasma membranes Pharmacol., Biochem. Behav. 1991, 40, 547-552
73. Guo, J.; Yang, D. P.; Chari, R.; Tian, X.; Pavlopoulos, S.; Lu, D.; Makriyannis, A. Magnetically aligned bicelles to study the orientation of lipophilic ligands in membrane bilayers J. Med. Chem. 2008, 51, 6793-6799
74. Mavromoustakos, T.; Yang, D. P.; Makriyannis, A. Topography of alphaxalone and delta 16-alphaxalone in membrane bilayers containing cholesterol Biochim. Biophys. Acta 1994, 1194, 69-74
75. Mavromoustakos, T.; Yang, D. P.; Makriyannis, A. Topography and thermotropic properties of cannabinoids in brain sphingomyelin bilayers Life Sci. 1996, 59, 1969-1979
76. Makriyannis, A.; Fesik, S. Mechanism of steroid anesthetic action: interactions of alphaxalone and delta 16-alphaxalone with bilayer vesicles J. Med. Chem. 1983, 26, 463-465
77. Piomelli, D.; Beltramo, M.; Glasnapp, S.; Lin, S. Y.; Goutopoulos, A.; Xie, X. Q.; Makriyannis, A. Structural determinants for recognition and translocation by the anandamide transporter Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 5802-5807
78. Calignano, A.; La Rana, G.; Beltramo, M.; Makriyannis, A.; Piomelli, D. Potentiation of anandamide hypotension by the transport inhibitor, AM404 Eur. J. Pharmacol. 1997, 337, R1-R2
79. Fowler, C. J. The cannabinoid system and its pharmacological manipulation - a review, with emphasis upon the uptake and hydrolysis of anandamide Fundam. Clin. Pharmacol. 2006, 20, 549-562
80. 19F-NMR study of a selective FAAH inhibitor binding with an anandamide carrier protein, HAS. J. Pharm. Pharmacol. 2013, 1, 002, DOI: 10.13188/12327-13204X.1000002.
81. Zhuang, J.; Yang, D. P.; Nikas, S. P.; Zhao, J.; Guo, J.; Makriyannis, A. The interaction of fatty acid amide hydrolase (FAAH) inhibitors with an anandamide carrier protein using (19)F-NMR AAPS J. 2013, 15, 477-482
82. Malan, T. P., Jr.; Ibrahim, M. M.; Vanderah, T. W.; Makriyannis, A.; Porreca, F. Inhibition of pain responses by activation of CB2 cannabinoid receptors Chem. Phys. Lipids 2002, 121, 191-200
83. Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fride, E. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14228-14233
84. Ibrahim, M. M.; Deng, H.; Zvonok, A.; Cockayne, D. A.; Kwan, J.; Mata, H. P.; Vanderah, T. W.; Lai, J.; Porreca, F.; Makriyannis, A.; Malan, T. P., Jr. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10529-10533
85. Nackley, A. G.; Makriyannis, A.; Hohmann, A. G. Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation Neuroscience 2003, 119, 747-757
86. Rahn, E. J.; Zvonok, A. M.; Makriyannis, A.; Hohmann, A. G. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation AAPS J. 2010, 12, 147-157
87. Quartilho, A.; Mata, H. P.; Ibrahim, M. M.; Vanderah, T. W.; Porreca, F.; Makriyannis, A.; Malan, T. P., Jr. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors Anesthesiology 2003, 99, 955-960
88. Hohmann, A. G.; Farthing, J. N.; Zvonok, A. M.; Makriyannis, A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin J. Pharmacol. Exp. Ther. 2004, 308, 446-453
89. Nackley, A. G.; Zvonok, A. M.; Makriyannis, A.; Hohmann, A. G. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation J. Neurophysiol. 2004, 92, 3562-3574
90. Ibrahim, M. M.; Porreca, F.; Lai, J.; Albrecht, P. J.; Rice, F. L.; Khodorova, A.; Davar, G.; Makriyannis, A.; Vanderah, T. W.; Mata, H. P.; Malan, T. P., Jr. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3093-3098
91. Ibrahim, M. M.; Rude, M. L.; Stagg, N. J.; Mata, H. P.; Lai, J.; Vanderah, T. W.; Porreca, F.; Buckley, N. E.; Makriyannis, A.; Malan, T. P., Jr. CB2 cannabinoid receptor mediation of antinociception Pain 2006, 122, 36-42
92. Khanolkar, A. D.; Lu, D.; Ibrahim, M.; Duclos, R. I., Jr.; Thakur, G. A.; Malan, T. P., Jr.; Porreca, F.; Veerappan, V.; Tian, X.; George, C.; Parrish, D. A.; Papahatjis, D. P.; Makriyannis, A. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity J. Med. Chem. 2007, 50, 6493-6500
93. Rahn, E. J.; Thakur, G. A.; Wood, J. A.; Zvonok, A. M.; Makriyannis, A.; Hohmann, A. G. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects Pharmacol., Biochem. Behav. 2011, 98, 493-502
94. Wilkerson, J. L.; Gentry, K. R.; Dengler, E. C.; Wallace, J. A.; Kerwin, A. A.; Kuhn, M. N.; Zvonok, A. M.; Thakur, G. A.; Makriyannis, A.; Milligan, E. D. Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia Brain Behav. 2012, 2, 155-177
95. Rahn, E. J.; Makriyannis, A.; Hohmann, A. G. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats Br. J. Pharmacol. 2007, 152, 765-777
96. Rahn, E. J.; Zvonok, A. M.; Thakur, G. A.; Khanolkar, A. D.; Makriyannis, A.; Hohmann, A. G. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats J. Pharmacol. Exp. Ther. 2008, 327, 584-591
97. Deng, L.; Guindon, J.; Vemuri, V. K.; Thakur, G. A.; White, F. A.; Makriyannis, A.; Hohmann, A. G. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy Mol. Pain 2012, 8, 71
98. Wilkerson, J. L.; Gentry, K. R.; Dengler, E. C.; Wallace, J. A.; Kerwin, A. A.; Armijo, L. M.; Kuhn, M. N.; Thakur, G. A.; Makriyannis, A.; Milligan, E. D. Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels Pain 2012, 153, 1091-1106
99. Bab, I.; Zimmer, A. Cannabinoid receptors and the regulation of bone mass Br. J. Pharmacol. 2008, 153, 182-188
100. Kim, K.; Moore, D. H.; Makriyannis, A.; Abood, M. E. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis Eur. J. Pharmacol. 2006, 542, 100-105
101. Storr, M. A.; Keenan, C. M.; Zhang, H.; Patel, K. D.; Makriyannis, A.; Sharkey, K. A. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis Inflammatory Bowel Dis. 2009, 15, 1678-1685
102. Xi, Z. X.; Peng, X. Q.; Li, X.; Song, R.; Zhang, H. Y.; Liu, Q. R.; Yang, H. J.; Bi, G. H.; Li, J.; Gardner, E. L. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice Nat. Neurosci. 2011, 14, 1160-1166
103. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor Science 2000, 289, 739-745
104. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields high-resolution structural insights into beta(2)-adrenergic receptor function Science 2007, 318, 1266-1273
105. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular signatures of G-protein-coupled receptors Nature 2013, 494, 185-194
106. Morse, K. L.; Fournier, D. J.; Li, X. Y.; Grzybowska, J.; Makriyannis, A. A novel electrophilic high-affinity irreversible probe for the cannabinoid receptor Life Sci. 1995, 56, 1957-1962
107. Picone, R. P.; Khanolkar, A. D.; Morse, K. L.; Reggio, P. H.; Fournier, D. J.; Makriyannis, A. Classical Cannabinoid Affinity Labels Suggest Different Binding Motifs on CB1 Receptors. Presented at the Symposium on the Cannabinoids, Burlington VT, 1999.
108. Chu, C.; Ramamurthy, A.; Makriyannis, A.; Tius, M. A. Synthesis of covalent probes for the radiolabeling of the cannabinoid receptor J. Org. Chem. 2003, 68, 55-61
109. Picone, R. P.; Fournier, D. J.; Makriyannis, A. Ligand based structural studies of the CB1 cannabinoid receptor J. Pept. Res. 2002, 60, 348-356
110. Zvonok, N.; Pandarinathan, L.; Williams, J.; Johnston, M.; Karageorgos, I.; Janero, D. R.; Krishnan, S. C.; Makriyannis, A. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis Chem. Biol. 2008, 15, 854-862
111. Zvonok, N.; Williams, J.; Johnston, M.; Pandarinathan, L.; Janero, D. R.; Li, J.; Krishnan, S. C.; Makriyannis, A. Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification J. Proteome Res. 2008, 7, 2158-2164
112. West, J. M.; Zvonok, N.; Whitten, K. M.; Wood, J. T.; Makriyannis, A. Mass spectrometric characterization of human N -acylethanolamine-hydrolyzing acid amidase J. Proteome Res. 2012, 11, 972-981
113. Filppula, S.; Yaddanapudi, S.; Mercier, R.; Xu, W.; Pavlopoulos, S.; Makriyannis, A. Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system J. Pept. Res. 2004, 64, 225-236
114. Xu, W.; Filppula, S. A.; Mercier, R.; Yaddanapudi, S.; Pavlopoulos, S.; Cai, J.; Pierce, W. M.; Makriyannis, A. Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system J. Pept. Res. 2005, 66, 138-150
115. Zvonok, N.; Xu, W.; Williams, J.; Janero, D. R.; Krishnan, S. C.; Makriyannis, A. Mass spectrometry-based GPCR proteomics: comprehensive characterization of the human cannabinoid 1 receptor J. Proteome Res. 2010, 9, 1746-1753
116. Zvonok, N.; Yaddanapudi, S.; Williams, J.; Dai, S.; Dong, K.; Rejtar, T.; Karger, B. L.; Makriyannis, A. Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor J. Proteome Res. 2007, 6, 2068-2079
117. Le Foll, B.; Gorelick, D. A.; Goldberg, S. R. The future of endocannabinoid-oriented clinical research after CB1 antagonists Psychopharmacology (Berlin, Ger.) 2009, 205, 171-174
118. Christensen, R.; Kristensen, P. K.; Bartels, E. M.; Bliddal, H.; Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 2007, 370, 1706-1713
119. Cosenza, M.; Gifford, A. N.; Gatley, S. J.; Pyatt, B.; Liu, Q.; Makriyannis, A.; Volkow, N. D. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281 Synapse 2000, 38, 477-482
120. Gatley, S. J.; Lan, R.; Volkow, N. D.; Pappas, N.; King, P.; Wong, C. T.; Gifford, A. N.; Pyatt, B.; Dewey, S. L.; Makriyannis, A. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo J. Neurochem. 1998, 70, 417-423
121. Lan, R.; Gatley, J.; Lu, Q.; Fan, P.; Fernando, S. R.; Volkow, N. D.; Pertwee, R.; Makriyannis, A. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand AAPS PharmSci 1999, 1, E4
122. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists J. Med. Chem. 1999, 42, 769-776
123. McLaughlin, P. J.; Qian, L.; Wood, J. T.; Wisniecki, A.; Winston, K. M.; Swezey, L. A.; Ishiwari, K.; Betz, A. J.; Pandarinathan, L.; Xu, W.; Makriyannis, A.; Salamone, J. D. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387 Pharmacol., Biochem. Behav. 2006, 83, 396-402
124. Le Foll, B.; Pushparaj, A.; Pryslawsky, Y.; Forget, B.; Vemuri, V. K.; Makriyannis, A.; Trigo, J. M. Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, DOI: 10.1016/j.pnpbp.2013.1010.1009.
125. Cluny, N. L.; Chambers, A. P.; Vemuri, V. K.; Wood, J. T.; Eller, L. K.; Freni, C.; Reimer, R. A.; Makriyannis, A.; Sharkey, K. A. The neutral cannabinoid CB(1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat Pharmacol., Biochem. Behav. 2011, 97, 537-543
126. Storr, M. A.; Bashashati, M.; Hirota, C.; Vemuri, V. K.; Keenan, C. M.; Duncan, M.; Lutz, B.; Mackie, K.; Makriyannis, A.; Macnaughton, W. K.; Sharkey, K. A. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice Neurogastroenterol. Motil. 2010, 22, 787-796
127. Salamone, J. D.; McLaughlin, P. J.; Sink, K.; Makriyannis, A.; Parker, L. A. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions Physiol. Behav. 2007, 91, 383-388
128. Sink, K. S.; McLaughlin, P. J.; Wood, J. A.; Brown, C.; Fan, P.; Vemuri, V. K.; Peng, Y.; Olszewska, T.; Thakur, G. A.; Makriyannis, A.; Parker, L. A.; Salamone, J. D. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats Neuropsychopharmacology 2008, 33, 946-955
129. Sink, K. S.; Segovia, K. N.; Collins, L. E.; Markus, E. J.; Vemuri, V. K.; Makriyannis, A.; Salamone, J. D. The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats Pharmacol., Biochem. Behav. 2010, 95, 479-484
130. Sink, K. S.; Segovia, K. N.; Sink, J.; Randall, P. A.; Collins, L. E.; Correa, M.; Markus, E. J.; Vemuri, V. K.; Makriyannis, A.; Salamone, J. D. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142 Eur. Neuropsychopharmacol. 2010, 20, 112-122
131. Sink, K. S.; Vemuri, V. K.; Wood, J.; Makriyannis, A.; Salamone, J. D. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113 Pharmacol., Biochem. Behav. 2009, 91, 303-306
132. Limebeer, C. L.; Vemuri, V. K.; Bedard, H.; Lang, S. T.; Ossenkopp, K. P.; Makriyannis, A.; Parker, L. A. Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats Br. J. Pharmacol. 2010, 161, 336-349
133. Hodge, J.; Bow, J. P.; Plyler, K. S.; Vemuri, V. K.; Wisniecki, A.; Salamone, J. D.; Makriyannis, A.; McLaughlin, P. J. The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats Behav. Brain Res. 2008, 193, 298-305
134. Bergman, J.; Delatte, M. S.; Paronis, C. A.; Vemuri, K.; Thakur, G. A.; Makriyannis, A. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties Physiol. Behav. 2008, 93, 666-670
135. Chambers, A. P.; Vemuri, V. K.; Peng, Y.; Wood, J. T.; Olszewska, T.; Pittman, Q. J.; Makriyannis, A.; Sharkey, K. A. A neutral CB1 receptor antagonist reduces weight gain in rat Am. J. Physiol.: Regul., Integr. Comp. Physiol. 2007, 293, R2185-2193
136. Janero, D. R.; Lindsley, L.; Vemuri, V. K.; Makriyannis, A. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk Expert Opin. Drug Discovery 2011, 6, 995-1025
137. Tam, J.; Vemuri, V. K.; Liu, J.; Batkai, S.; Mukhopadhyay, B.; Godlewski, G.; Osei-Hyiaman, D.; Ohnuma, S.; Ambudkar, S. V.; Pickel, J.; Makriyannis, A.; Kunos, G. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J. Clin. Invest. 2010, 120, 2953-2966
138. Cluny, N. L.; Vemuri, V. K.; Chambers, A. P.; Limebeer, C. L.; Bedard, H.; Wood, J. T.; Lutz, B.; Zimmer, A.; Parker, L. A.; Makriyannis, A.; Sharkey,
139. Randall, P. A.; Vemuri, V. K.; Segovia, K. N.; Torres, E. F.; Hosmer, S.; Nunes, E. J.; Santerre, J. L.; Makriyannis, A.; Salamone, J. D. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior Pharmacol., Biochem. Behav. 2010, 97, 179-184
140. Sharma, R.; Nikas, S. P.; Paronis, C. A.; Wood, J. T.; Halikhedkar, A.; Guo, J. J.; Thakur, G. A.; Kulkarni, S.; Benchama, O.; Raghav, J. G.; Gifford, R. S.; Jarbe, T. U.; Bergman, J.; Makriyannis, A. Controlled-deactivation cannabinergic ligands J. Med. Chem. 2013, 56, 10142-10157
141. Sharma, R.; Guo, N. S.; Mallipeddi, J. J.; Wood, S.; Makriyannis, J. T. C-ring cannabinoid lactones: a novel cannabinergic chemotype ACS Med. Chem. Lett. 2014, 5, 400-404
142. Deutsch, D. G.; Lin, S.; Hill, W. A.; Morse, K. L.; Salehani, D.; Arreaza, G.; Omeir, R. L.; Makriyannis, A. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor Biochem. Biophys. Res. Commun. 1997, 231, 217-221
143. Deutsch, D. G.; Makriyannis, A. Inhibitors of anandamide breakdown NIDA Res. Monogr. 1997, 173, 65-84
144. Qin, C.; Lin, S.; Lang, W.; Goutopoulos, A.; Pavlopoulos, S.; Mauri, F.; Makriyannis, A. Determination of anandamide amidase activity using ultraviolet-active amine derivatives and reverse-phase high-performance liquid chromatography Anal. Biochem. 1998, 261, 8-15
145. Lang, W.; Qin, C.; Hill, W. A.; Lin, S.; Khanolkar, A. D.; Makriyannis, A. High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes Anal. Biochem. 1996, 238, 40-45
146. Qin, C. Purificaion and Charaterization of Anandamide Amidase and Development of Novel Inhibitors. Ph.D. Thesis, University of Connecticut, Storrs, CT, 1998.
147. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling Science 2002, 298, 1793-1796
148. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies J. Med. Chem. 2004, 47, 4998-5008
149. Karanian, D. A.; Brown, Q. B.; Makriyannis, A.; Kosten, T. A.; Bahr, B. A. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity J. Neurosci. 2005, 25, 7813-7820
150. Karanian, D. A.; Karim, S. L.; Wood, J. T.; Williams, J. S.; Lin, S.; Makriyannis, A.; Bahr, B. A. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage J. Pharmacol. Exp. Ther. 2007, 322, 1059-1066
151. Bahr, B. A.; Karanian, D. A.; Makanji, S. S.; Makriyannis, A. Targeting the endocannabinoid system in treating brain disorders Expert Opin. Invest. Drugs 2006, 15, 351-365
152. Karanian, D. A.; Brown, Q. B.; Makriyannis, A.; Bahr, B. A. Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus Eur. J. Pharmacol. 2005, 508, 47-56
153. Johnson, D. S.; Stiff, C.; Lazerwith, S. E.; Kesten, S. R.; Fay, L. K.; Morris, M.; Beidler, D.; Liimatta, M. B.; Smith, S. E.; Dudley, D. T.; Sadagopan, N.; Bhattachar, S. N.; Kesten, S. J.; Nomanbhoy, T. K.; Cravatt, B. F.; Ahn, K. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor ACS Med. Chem. Lett. 2011, 2, 91-96
154. Rengachari, S.; Aschauer, P.; Gruber, K.; Dreveny, I.; Oberer, M. Crystal structure of monoacylglycerol lipase from Bacillus sp. H257 in complex with monopalmitoylglycerol analog J. Biol. Chem. 2013, 288, 31093-311104
155. Schalk-Hihi, C.; Schubert, C.; Alexander, R.; Bayoumy, S.; Clemente, J. C.; Deckman, I.; DesJarlais, R. L.; Dzordzorme, K. C.; Flores, C. M.; Grasberger, B.; Kranz, J. K.; Lewandowski, F.; Liu, L.; Ma, H.; Maguire, D.; Macielag, M. J.; McDonnell, M. E.; Mezzasalma Haarlander, T.; Miller, R.; Milligan, C.; Reynolds, C.; Kuo, L. C. Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolution Protein Sci. 2011, 20, 670-683
156. Karageorgos, I.; Wales, T. E.; Janero, D. R.; Zvonok, N.; Vemuri, V. K.; Engen, J. R.; Makriyannis, A. Active-site inhibitors modulate the dynamic properties of human monoacylglycerol lipase: a hydrogen exchange mass spectrometry study Biochemistry 2013, 52, 5016-5026
157. Ramesh, D.; Gamage, T. F.; Vanuytsel, T.; Owens, R. A.; Abdullah, R. A.; Niphakis, M. J.; Shea-Donohue, T.; Cravatt, B. F.; Lichtman, A. H. Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice Neuropsychopharmacology 2013, 38, 1039-1049
158. Long, J. Z.; Nomura, D. K.; Vann, R. E.; Walentiny, D. M.; Booker, L.; Jin, X.; Burston, J. J.; Sim-Selley, L. J.; Lichtman, A. H.; Wiley, J. L.; Cravatt, B. F. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 20270-20275